Blood Amyloid-beta Oligomerization as a Biomarker of Alzheimer's Disease: A Blinded Validation Study

초록

Background: Oligomeric amyloid-beta (A beta) is one of the major contributors to the pathomechanism of Alzheimer's disease (AD); A beta oligomerization in plasma can be measured using a Multimer Detection System-Oligomeric A beta (MDS-OA beta) after incubation with spiked synthetic A beta. Objective: We evaluated the clinical sensitivity and specificity of the MDS-OA beta values for prediction of AD. Methods: The MDS-OA beta values measured using in Blood (TM) OA beta test in heparin-treated plasma samples from 52ADpatients in comparison with 52 community-based subjects with normal cognition (NC). The inclusion criterion was proposed by the NINCDS-ADRDA and additionally required at least 6 months of follow-up from the initial clinical diagnosis in the course of AD. Results: The MDS-OA beta values were 1.43 +/- 0.30 ng/ml in AD and 0.45 +/- 0.19 (p < 0.001) in NC, respectively. Using a cut-off value of 0.78 ng/ml, the results revealed 100% sensitivity and 92.31% specificity. Conclusion: MDS-OA beta to measure plasma A beta oligomerization is a valuable blood-based biomarker for clinical diagnosis of AD, with high sensitivity and specificity.

키워드